Anti-PD-L1-SAP [IT-45, KIT-45]

anti-human PD-L1-saporin

SKU: IT-45 Category: Quantity: Individual 25 ug, Individual 100 ug, Individual 250 ug, Individual 1 mg, Kit w/controls 25 ug, Kit w/controls 100 ug, Kit w/controls 250 ug | Antibody Type: Polyclonal | Host: rabbit | Reactivity: human | Conjugate: streptavidin-saporin | Usage: eliminates cells, retrograde transport |

PD-L1, Programmed death-ligand 1, also known as B7-H1 and CD274, is a cell surface glycoprotein and a member of the B7 family of co-stimulatory molecules. CD274 is expressed constitutively on macrophages and dendritic cells, and is induced on activated T-cells, B-cells, endothelial cells and epithelial cells in response to interferons. PD-L1 has dual function: inhibition of activated effector T cells and co-stimulation of naive T cells. PD-L1 has also been shown to be up-regulated in cancer cells in order to invade the host immune system.  Anti-PD-L1-SAP could be used as an effective tool to study cancer and the immune system.

Anti-PD-L1-SAP is a bonded conjugate between a mouse monoclonal antibody to human PD-L1 (CD274, B7-H1) and the secondary conjugate Streptavidin-ZAP (IT-27) containing the ribosome-inactivating protein, saporin. It specifically eliminates cells expressing human PD-L1 (CD274, B7-H1).

Anti-PD-L1-SAP is available individually (Cat. #IT-45) or as a kit (Cat. #KIT-45) which includes Anti-PD-L1-SAP and BIgG-SAP Mouse (Cat. #IT-74).

keywords: Programmed death ligand, B7-H1, PD-L1, CD274, immune, T cells, cancer, PD-1, pregnancy, allografts, hepatitis, B cells, myeloid cells, interferons, nk cells, macrophages, hepatocytes, monocytes, tumor, BETA-014, biotinylated, strepatavidin, saporin

Reviews

There are no reviews yet.

Be the first to review “Anti-PD-L1-SAP [IT-45, KIT-45]”

View Data Sheet

Light-controlled elimination of PD-L1+ cells

Wong JJW, Selbo PK (2021) Light-controlled elimination of PD-L1+ cells. J Photochem Photobiol B 225:112355. doi: 10.1016/j.jphotobiol.2021.112355

Objective: To investigate novel strategies that simultaneously target both tumor cells and immunosuppressive cells in the tumor microenvironment. The focus was on the evaluation in vitro of Anti-PD-L1-SAP combined with photochemical internalization (PCI) as a therapeutic strategy to target and eliminate PD-L1 expressing tumor and immunosuppressive cells.

Summary: The authors show that the intracellular light-controlled drug delivery method induces specific and strongly enhanced cytotoxic effects of Anti-PD-L1-SAP in the PD-L1+ triple-negative breast cancer MDA-MB-231 cell line, while no enhanced efficacy was obtained in the PD-L1 negative control cell line MDA-MB-453. 

Usage: Anti-PD-L1-SAP and Streptavidin-ZAP (Control) were used in a cytotoxicity assay.

Related Products: Anti-PD-L1-SAP (Cat. #IT-45), Streptavidin-ZAP (Cat. #IT-27)

browse all references for this product | back to top

browse all protocols and calculators | back to top

Shopping Cart
Scroll to Top